Moberg Pharma signs deal to acquire OTC brands in the U.S.

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Moberg Pharma signs deal to acquire OTC brands in the U.S.

Moberg Pharma AB (OMX: MOB) has signed a deal to acquire three well established Over-The-Counter brands in the U.S. from Bayer HealthCare, LLC. Total annual sales for the brands are approximately 20 MSEK (ca 3 m$). The purchase price is 32 MSEK (4.8 m$) and is financed by available cash resources. The acquired portfolio includes Domeboro®, a topical astringent used for relieving itch and minor skin irritations; Vanquish®, an internal analgesic; and Fergon®, an iron supplement. The brands will be sold through Moberg’s current channel, primarily in chain drugstores and mass retailers, such as Walmart. “It is with great pleasure that I present this acquisition. We have worked to achieve this kind of deal since we acquired Alterna LLC a year ago, when we established our own presence in the U.S. Today’s deal will very nicely leverage our U.S. sales platform, it contributes immediately to our sales and earnings and to our long term financial goal of achieving an EBITDA margin of 25%”, said Peter Wolpert, CEO of Moberg Pharma AB. Commenting on the transaction, Erica Mann, president, Bayer HealthCare, Consumer Care said, “We are pleased to sell these brands to Moberg following our realigned strategic focus and portfolio review. The transaction will allow us to further focus on our core brands and global brand expansion in the U.S. and other markets as we work to significantly strengthen our OTC business.” The transaction is expected to close before the end of 2013. About this information Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08.00 am (CET) on December 6th, 2013. For further information, please contact: Peter Wolpert, CEO, Moberg Pharma AB, telephone: +46 707 35 71 35, e-mail: peter.wolpert@mobergpharma.se Peter Östling, IR, Moberg Pharma AB, telephone: +46 76 314 09 78, e-mail: peter.ostling@mobergpharma.se About Moberg Pharma AB Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with direct sales through its own sales organization in the US and sales through distributors in more than 40 countries. The company’s product portfolio includes topical products for the treatment of skin disorders and pain under the brands Kerasal®, Jointflex®, Kerasal Nail™ and Kaprolac®. Kerasal Nail™ (Nalox™ in many markets) is the leading product for the treatment of nail disorders in the Nordic market. The portfolio is developed further through acquisitions and in -licensing of products as well as product development with focus on innovative drug delivery based on proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s share (OMX: MOB) is listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.com.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beta Bionics Hit with Lawsuit Over Misleading Claims

Updated Category News Views 6

Unpacking Beta Bionics' Legal Storm Investors in Beta Bionics, Inc. —ticker BBNX—are probably feeling like they're caught in a whirlwind right now, and who can blame them? The company's facing a class action lawsuit, and the accusations aren't anything to sniff at. They're talking about violations of the Securities Exchange Act of 1934, along with some shady...

Continue Reading
Mountain Living: Facing the Population Growth Crunch

Updated Category News Views 0

Population Growth Reshaping U.S. Mountain Communities Living in a picturesque mountain town used to offer an idyllic escape from the hustle and bustle of city life. But now, even these scenic enclaves are feeling the squeeze from a wave of population growth that's hard to ignore. Mark Cromer tackles this head-on in his new Forum paper, 'The Long Goodnight of Rocky...

Continue Reading
Kenneth Spells: Championing Education Leadership in 2026

Updated Category News Views 3

Out there in Hoke County, you’ve got a man named Kenneth Spells shaking things up the way a strong leader should. Now, you know I’m not here to fluff up anyone’s feathers—especially in an arena as aching for reform as education. But credit where credit’s due, Spells picked up the ‘2026 Professional of the Year’ from The Inner Circle for a reason, and it’s...

Continue Reading
XTI Aerospace Eyes Growth Amid Revenue Slip

Updated Category News Views 4

A Second Quarter Snapshot Ah, the world of aerospace—where soaring ambitions often face a reality check. XTI Aerospace, hitching a ride on the drone tech boom, found itself dealing with a mixed bag this past second quarter. Coming from the streets of Miami with its quarterly numbers, XTI's interim CEO Jeremy Schneiderman is banking on drones to lift their revenue skies....

Continue Reading
DICK'S Sporting Goods Faces Legal Challenges in Securities Suit

Updated Category News Views 4

Trouble Brewing at DICK'S Sporting Goods Wall Street's not only about the wins. There are moments when the market throws a curveball, and right now, DICK'S Sporting Goods is facing a fast one. DJS Law Group just laid out a class action lawsuit accusing them of bending the securities law rules. It ain't pretty when a company gets tangled up in legal battles, but it's...

Continue Reading
Meitav Tops 2025 Service Index with Stellar Growth

Updated Category News Views 6

Meitav’s Leap to The Summit Damn, it's a wild market when a pension fund provider snatches the crown. But here we are, looking at Meitav Provident Funds and Pension Ltd., standing proudly as Israel's top dog in the 2025 Service Index for pension funds. We're talking a jump from fourth to numero uno, folks, with a hefty score of 83 out of 100. And don't sleep on their...

Continue Reading
CAR T-Cell Therapy Offers New Hope for SPS Patients

Updated Category News Views 0

Game-changing Developments in CAR T-Cell Therapy Leaping straight into the meat of it—our friends at the University of Colorado Anschutz are onto something big. They've wrapped up a study pushing the boundaries of CAR T-cell therapy, and let me tell you, it looks like a real game-changer for those battling the rare beast known as stiff person syndrome (SPS). Breaking...

Continue Reading
Software Tax Hits Enterprises: Costly Control Concerns

Updated Category News Views 16

Unanticipated Software Costs: Who's in Charge? Picture this: you're running a tech setup at a major corporation, but the software changes thrust upon you aren't anything you would've chosen freely. Yeah, that's about one in four dollars from your hot little budget spent on tweaks and adjustments you didn’t ask for. And it's not as glamorous as it sounds—more like a...

Continue Reading
Jackson Hewitt Aims to Recruit 15,000 Seasonal Staff

Updated Category News Views 8

Revving Up for Tax Season: Jackson Hewitt's Hiring Push When tax season looms, the hustle can't be understated, and Jackson Hewitt is cranking it up by hunting for 15,000 new recruits to tackle this annual financial circus. Starting October 26, this hiring fest is open season across the nation, pulling out all the stops to bolster its workforce. But what does this mean...

Continue Reading
Tax Strategy Crucial: Sidnell & Webster of Lufkin Weigh In

Updated Category News Views 4

Breaking Down Tax Prep vs. Planning Ever wonder why some folks never break a sweat come tax season, while others scramble like their hair's on fire? It all boils down to understanding two very different animals: tax preparation and tax planning. CPA veterans Yvette Sidnell and Jennifer Webster over in Lufkin, Texas, have laid it out crystal clear in their article with...

Continue Reading

Top 5 Most Recently Viewed Articles

Rancho Mission Viejo: Leading the Way in Wellness Real Estate

Updated Category News Views 202

Rancho Mission Viejo Recognized Globally for Wellness Development The Ranch stands out as a model for wellness communities and showcases the impact on individual lives. This 23,000-acre master-planned community and functional cattle ranch has achieved global recognition as one of the largest intentional wellness real estate developments. A Testament to Community Design As...

Continue Reading
Revolutionizing Patient Access with AI: The New Trial Finder

Updated Category News Views 177

Introducing the Future of Clinical Trials The world of radiopharmaceuticals is changing rapidly, with an innovative new tool set to revolutionize the way patients and healthcare providers access critical information about clinical trials. The Radiopharmaceutical Trial Finder, backed by the ICPO Foundation, was developed through a collaboration between WARMTH and...

Continue Reading
Semler Scientific Faces Legal Challenges Amid Controversy

Updated Category News Views 157

Semler Scientific Under Legal Scrutiny Semler Scientific, Inc. is currently facing a class action lawsuit that sheds light on serious allegations regarding their securities practices. Shareholders of the company, identified by the ticker SMLR, are encouraged to be proactive amidst these developments. The lawsuit primarily alleges violations of federal securities exchanges...

Continue Reading
Charles Dayoub Joins The Willis Law Group Fraud Team

Updated Category News Views 207

Charles Dayoub Enhances The Willis Law Group’s Fraud Team We are delighted to announce that Charles Dayoub has joined The Willis Law Group P.L.L.C., bringing with him a wealth of experience with over 18 years in law and extensive expertise in executive positions. His previous role at a prominent law firm involved dealing with government receivables and regulatory...

Continue Reading
Evaluating Revolution Medicines' Future Potential and Progress

Updated Category News Views 168

Revolution Medicines Maintains Positive Outlook Piper Sandler has sustained an optimistic outlook regarding Revolution Medicines (NASDAQ: RVMD), reaffirming its Overweight rating with a specified price target of $57.00. This commitment to the stock's rating comes after recent developments linked to the company’s Phase I trial, which is focused on RMC-6236, a potential...

Continue Reading